Home/Achalasia
Condition Deep-Dive

Achalasia

A rare esophageal motility disorder where the lower esophageal sphincter fails to relax, preventing food from passing into the stomach. Requires medical or surgical treatment; nutrition focuses on consistency modifications, upright posture and weight maintenance.

Gut & Digestive Evidence-Based

Last updated:

Definition

What Is Achalasia?

Achalasia is a rare neurodegenerative disorder of the esophagus. The lower esophageal sphincter (LES, the muscular valve between esophagus and stomach) fails to relax properly during swallowing, and the muscular wall of the esophagus loses its coordinated peristaltic contractions. Food and liquids accumulate in the esophagus, causing progressive dilation and severe swallowing difficulty.

The underlying cause is destruction of inhibitory neurons in the myenteric plexus of the esophagus; autoimmune, viral or genetic mechanisms are suspected, but the precise trigger remains unclear in most cases. Chagas disease (Trypanosoma cruzi infection) causes a similar picture in endemic areas.

Achalasia is rare: about 1 to 2 people in 100,000 are diagnosed each year, and it affects both sexes and all ages1. While achalasia is not curable, modern treatments (Heller myotomy, POEM, pneumatic dilation) provide excellent symptom relief for most patients.

โš ๏ธ Untreated achalasia causes progressive esophageal dilation (megaesophagus), increased aspiration pneumonia risk, malnutrition and a raised risk of esophageal squamous cell cancer, reported as roughly 5 to 15 times that of the general population. The absolute risk stays low, in the region of 1.4 cases per 1,000 person-years, and routine endoscopic surveillance has not been shown to improve survival, so it is not currently recommended. Early diagnosis and treatment of the achalasia itself are what matter.2
The esophagus widened into a sac above a tight ring of muscle that will not open into the stomach, with swallowed food trapped inside the sac

Chicago Classification: Types of Achalasia

Type I (Classic)

Aperistalsis, no contractions in the esophagus. About 1 in 5 cases in the original classification series3. Often presents later with significant dilation. Responds well to all standard treatments.

Type II (Compression)

Aperistalsis with panesophageal pressurization.4 The most common subtype, about half of cases in the original classification series3. Best treatment response. Heller myotomy or POEM typically very effective.

Type III (Spastic)

Premature spastic contractions in distal esophagus. About 3 in 10 cases in the original classification series3. Worst treatment response with standard surgical options. POEM with extended myotomy preferred.

By the Numbers

Achalasia by the Numbers

About 1 in 100,000
people are diagnosed each year, or up to about 2 in 100,000 in some estimates, which makes achalasia rare1
10 to 15.7 in 100,000
people are living with achalasia at any one time, and it affects both sexes and all ages1
5 to 15ร—
the general population's risk of esophageal cancer, though the absolute yearly risk stays low and routine screening is not currently recommended2
27 to 42%
of people with achalasia also have heartburn, which is why it is often first treated as reflux5
88 to 95%
success for surgical myotomy in a systematic review of 93 studies, against 70 to 90% for balloon dilation6
10 to 20%
have symptoms come back in the long term after surgical myotomy, and can be treated again1
Signs & Symptoms

Symptoms of Achalasia

Symptoms develop slowly over months to years. The classic tetrad: dysphagia, regurgitation, chest pain, weight loss. Often misdiagnosed as GERD initially.

SymptomWhat happens
Primary Symptoms
Dysphagia (Difficulty Swallowing)Hallmark symptom. Trouble swallowing both solids and liquids, often from early on, which is unusual for other esophageal conditions. Feeling food "stuck" behind the sternum.
Regurgitation of Undigested FoodBringing up food that has not been mixed with stomach acid (unlike GERD reflux). Often occurs hours after eating, especially when lying down. Significant aspiration risk during sleep.
Chest PainSubsternal pain, often with eating or spontaneously. Particularly common in Type III (spastic) achalasia. Sometimes mistaken for cardiac chest pain; cardiac causes must be ruled out.
Weight LossFrom reduced intake: patients learn to avoid foods that get stuck. Significant unintentional weight loss is common, particularly in advanced disease.
Secondary & Complication Signs
Nocturnal Coughing / AspirationFood/saliva pooled in esophagus aspirates into airways when lying down7. Causes nocturnal cough, recurrent pneumonia and morning hoarseness.
Increased Salivation & DroolingCompensatory mechanism, saliva helps "wash" food down. Many patients carry water bottles constantly and develop maneuvers (arching back, deep breaths) to push food through.
Eating Behaviors & Food AvoidanceEating very slowly, drinking lots of water with meals, avoiding fibrous/dry foods (meat, bread). Some patients only eat alone due to embarrassment. Major quality of life impact.
Megaesophagus (Late Stage)In advanced disease, esophagus dilates to massive proportions and develops sigmoid (S-shape) configuration. Severe symptoms; esophagectomy may be needed when other treatments fail. Preventable with earlier treatment.
Causes

Causes of Achalasia

Achalasia follows the loss of the nerves that let the lower esophageal sphincter relax; why they are lost remains unknown in most people5.

CauseHow It Contributes to AchalasiaWhat Helps
Loss of the nerves that relax the sphincterSelective loss of inhibitory nerves in the esophageal wall leaves the sphincter unable to relax and the swallowing waves disordered5.Endoscopic or surgical myotomy or balloon dilation to open the sphincter (conventional care); eating upright, small moist bites and water with meals (Nutritional Strategy)
An immune reaction in a predisposed personThe leading explanation, not yet proven, is an autoimmune attack on those nerves, triggered by a viral infection in someone genetically predisposed; achalasia has been reported in identical twins, siblings and other close relatives8.Nothing is known to prevent it; treatment is the same (conventional care)
Chagas diseaseInfection with the parasite Trypanosoma cruzi, found in parts of Central and South America, damages the same nerves and causes a secondary achalasia9.A blood test when there has been exposure (Diagnosis); the same treatments, chosen with the heart in mind, since Chagas disease can also affect it (conventional care)
A tumor at the junction that mimics itA cancer where the esophagus meets the stomach can look exactly like achalasia; in a review of 140 such cases, about 1 in 4 were first treated as achalasia10.Upper endoscopy for everyone with suspected achalasia, before treatment (conventional care)
Long-term opioid medicinesChronic opioid use can produce a picture identical to the spastic type of achalasia11.A review of pain medicines with the prescriber, never stopping on your own (conventional care)
Diagnosis

How Achalasia Is Diagnosed

TestWhat it shows
Primary Diagnostic Tests
High-Resolution Esophageal Manometry (HRM)Gold standard. Measures pressure throughout esophagus during swallowing using catheter. Diagnoses achalasia and classifies into Type I, II or III (Chicago Classification 4.0). Essential for treatment planning.
Barium Esophagram (Swallow Study)Classic "bird's beak" appearance at LES with dilated proximal esophagus. Timed barium swallow measures column height to assess severity and treatment response. Visualizes degree of dilation.
Upper Endoscopy (EGD)Excludes pseudoachalasia (cancer at GE junction mimicking achalasia), retained food in esophagus, esophagitis. ALL patients with new suspected achalasia need EGD to rule out malignancy.
Adjunct Workup
Chagas Disease Workup (If Indicated)In endemic areas (Central/​South America) or with risk exposure, serology for Trypanosoma cruzi. Chagas causes "secondary achalasia" with similar symptoms.
EndoFLIP (Endoscopic Functional Luminal Imaging Probe)Newer technology measures LES distensibility. Useful when manometry results are equivocal. Increasingly used intra-operatively to guide myotomy.
Nutritional WorkupAlbumin, prealbumin, fat-soluble vitamins, iron studies and B12 to assess malnutrition state. Severe weight loss may need pre-procedure nutritional optimization.
Eckardt Symptom ScoreValidated symptom scoring (dysphagia, regurgitation, chest pain, weight loss). Used to assess severity and treatment response. In most trials a score above 3 counts as treatment failure, so 3 or less is taken as success1.
Treatment Comparison

Conventional and Holistic Treatment for Achalasia

๐ŸŒฟ HOLISTIC
๐Ÿ’Š CONVENTIONAL
๐ŸŒฟ

Holistic / Functional Approach

Dietary modification, eating mechanics, upright positioning, nutritional support, ADJUNCT to medical/​surgical care, not replacement

The Reality
Achalasia is a structural disease that nutrition alone CANNOT cure, but quality of life can be significantly improved
Eating Mechanics
Small bites, chew thoroughly12, drink water between bites, stay upright 2 to 3 hours after meals
Nutritional Support
Maintain weight pre-procedure; replete fat-soluble vitamins and minerals; support healing post-procedure
When to Refer
Persistent trouble swallowing, weight loss or repeated aspiration: see an esophageal specialist promptly

Full Holistic Approach Includes

  • Eat upright: gravity helps food pass through the non-functioning LES
  • Drink lots of water with meals: helps wash food through; carbonated water can briefly distend LES (controversial, but some patients find it helpful)
  • Small, frequent meals, 5 to 6 smaller meals easier than 3 large ones
  • Chew thoroughly: semi-liquid consistency passes more easily
  • Avoid lying down 2 to 3 hours post-meal: reduces regurgitation and aspiration risk overnight
  • Elevate head of bed, 6 to 8 inches (15 to 20 cm) with bed risers or a wedge pillow
  • Pre-procedure nutrition support: protein, calorie and vitamin repletion before surgery improves outcomes
  • Post-procedure stepwise diet, liquids โ†’ puree โ†’ soft โ†’ regular as healing progresses
  • Address common deficiencies: B12, iron, vitamin D and fat-soluble vitamins, which can run low when intake has been poor; ask your clinician which are worth checking
  • Mental health support: difficult eating has a major psychosocial impact, and therapy or support groups help
โš ๏ธ Critical: Achalasia requires definitive treatment (Heller myotomy, POEM or pneumatic dilation) to prevent progressive damage. Nutrition supports BUT DOES NOT REPLACE these interventions. Don't delay treatment hoping for "natural" improvement.
Supplement Protocol

Evidence-Based Supplements for Achalasia

These supplements address malnutrition states common in achalasia and support recovery post-procedure.

SupplementWhat it is forTypical rangeTimingNotes & cautions
Liquid MultivitaminPre- and post-procedure nutritional support. Liquid form bypasses chewing/​swallowing difficulty.1 daily servingWith breakfast smoothieComprehensive coverage for malnourished patients.
Vitamin B12Can run low from poor intake, and long-term acid suppression after treatment can reduce absorption. Sublingual forms help when swallowing tablets is difficult12.1,000 mcg sublingual/dayAny timeTest serum B12 and methylmalonic acid.
Iron (Bisglycinate)Common deficiency from poor intake. Bisglycinate is well-tolerated; less constipating than other forms.25 to 50 mg elemental iron/day if deficientEmpty stomach + Vitamin C if toleratedTest ferritin and transferrin saturation. The top of this range sits above the 45 mg/day tolerable upper intake level for adults. That is appropriate only when correcting a confirmed deficiency under clinical supervision, not as general supplementation. Test ferritin first, and retest rather than staying on it indefinitely.
Vitamin D3 + K2Deficiency common from poor intake. Critical for bone health, especially in young patients.D3: Set the dose with your clinician; most adults need no blood test first; K2: 100 to 200 mcgWith fat mealIf you take warfarin, clear any vitamin K supplement with the clinician managing your anticoagulation before starting or stopping it: vitamin K antagonizes warfarin, and changing your intake destabilizes the INR. Consistency matters more than avoidance. This does not apply in the same way to direct oral anticoagulants such as apixaban or rivaroxaban, but tell your prescriber about any supplement you take.
Magnesium GlycinateCan run low when intake is poor. Supports normal muscle function; there is no evidence that it relieves esophageal spasm in achalasia.200 to 400 mg elemental/​nightBefore bedGlycinate is a gentle form. Avoid it, or take it only on medical advice, if you have reduced kidney function; take it 2 hours apart from bisphosphonate bone medicines, and ask your pharmacist about timing with antibiotics16. The top of this range is above the 350 mg/day upper intake level for supplemental magnesium; above that, diarrhea is common.
Probiotic (Saccharomyces boulardii)Useful especially around procedures and when antibiotics needed. Supports gut microbiome.500 mg (about 10 billion CFU) once or twice a dayWith mealsSafe with most medications. Use caution with immunosuppression or a central line, as yeast bloodstream infections have been reported; discuss with your team.
GlutamineProposed to support mucosal healing; it has not been tested after myotomy or dilation.5 to 10 g/dayIn smoothies between mealsTasteless. Evidence of benefit in recovery after achalasia treatment is lacking.
What to Expect

What to Expect Over Time

Achalasia is lifelong, but treatment that opens the sphincter relieves symptoms for most people, and eating habits make meals safer.

Treatment and supportive care, together
First Weeks

Upper endoscopy comes first for everyone, to rule out a tumor that mimics achalasia; manometry and a barium swallow confirm it and show the subtype5. Eating upright, small moist bites with water and waiting 2 to 3 hours before lying down start now, and weight is kept up before any procedure12.

Months 1 to 3

Treatment is chosen by subtype: endoscopic or surgical myotomy, or graded balloon dilation13. Botulinum injections give short-term relief only and suit people unfit for these1. Dilation carries a perforation risk of about 1.9%5. After a procedure, food is reintroduced in steps.

Months 3 to 12

Reflux is common after myotomy, especially the endoscopic kind: in one trial, 41% had esophageal inflammation 2 years after it, against 7% after dilation5. Follow-up endoscopy is suggested after a myotomy without an anti-reflux wrap1.

Long Term

Symptoms return in 10 to 20% in the long term after surgical myotomy and can be treated again1. Cancer risk is raised but low in absolute terms: routine screening is not advised, but returning symptoms in long-standing achalasia call for a low threshold for endoscopy1.

When to Seek Care

Food stuck that will not pass, especially if you cannot swallow your own saliva, needs emergency care17. Feeling suddenly unwell after a dilation or myotomy needs same-day emergency care, since perforation is the most serious complication and delay makes it more dangerous18. See your specialist promptly for returning swallowing trouble, weight loss or nighttime coughing. Get a same-day appointment for repeated chest infections, which need a review, not just another course of antibiotics7.

📬

Get new guides in your inbox. Once a month: new condition guides and research updates, including the trials that did not work. Free, no spam, and you can unsubscribe in one click.

Sign up

Next Steps

Achalasia Requires Specialist Care

This rare condition needs definitive treatment (POEM, Heller myotomy or dilation) to prevent progressive damage. Nutrition supports the journey but cannot replace these interventions. Find an esophageal motility specialist for optimal outcomes.

Explore Esophageal Cancer โ†’ Explore GERD (Acid Reflux) โ†’

References & Evidence Notes

Each numbered entry below is either a source you can follow or a note setting out what the evidence does and does not support. Both are numbered together so the markers in the text line up.

Last reviewed October 20, 2026. Supplement entries are cross-checked against the NIH National Center for Complementary and Integrative Health and the Linus Pauling Institute Micronutrient Information Center.19 Achalasia is a mechanical and neurological failure of the lower esophageal sphincter to relax. No diet, supplement or eating technique can fix that. What nutrition can do is keep weight and micronutrients up while you wait for treatment, make swallowing safer and more comfortable, and support healing afterward. That is genuinely worth doing, and it is not treatment. New or worsening difficulty swallowing, food sticking, regurgitation, unintentional weight loss or coughing at night belongs with a gastroenterologist, not a diet change. Untreated achalasia progresses.

  1. On incidence and follow-up: the 2020 European achalasia guideline estimates that 1.07 to 2.2 people per 100,000 are diagnosed each year and that 10 to 15.7 per 100,000 are living with achalasia, across both sexes and all ages. It notes that most trials count an Eckardt score above 3 as treatment failure, reserves botulinum toxin for people unfit for more invasive treatment, and reports symptom relapse in 10 to 20% in the long term after surgical myotomy, treatable with dilation, endoscopic myotomy or repeat surgery, suggests follow-up endoscopy for reflux after myotomy without an anti-reflux procedure, and advises against systematic cancer screening while keeping a low threshold for endoscopy with recurrent symptoms in long-standing disease, PubMed 32213062. ↩
  2. On esophageal cancer risk in achalasia: population-based studies report squamous cell carcinoma risk in the region of 5 to 15 times that of the general population, with absolute incidence around 1.4 cases per 1,000 person-years in cohort data. Endoscopic surveillance has not been shown to improve survival and is not currently recommended, and there is no consensus on screening intervals. The relative risk is real; the absolute yearly risk is low. Both facts belong together, because the relative figure alone is frightening and unactionable. ↩
  3. On subtype proportions: in the high-resolution manometry series that defined the three subtypes, 99 newly diagnosed patients comprised 21 with Type I, 49 with Type II and 29 with Type III, and Type II patients were the most likely to respond to any treatment, PubMed 18722376. ↩
  4. On subtypes: the Chicago Classification defines three manometric patterns: Type I (absent contractility), Type II (panesophageal pressurization) and Type III (spastic). Type II is the most common and has the best response to treatment; Type III responds least well to pneumatic dilation and is the main reason POEM with an extended myotomy is chosen. Reported proportions vary between series. ↩
  5. On diagnosis and treatment: the 2020 American College of Gastroenterology guideline notes that the cause of achalasia is unknown and is believed to be loss of the inhibitory nerves of the lower esophagus; that heartburn occurs in 27% to 42% of patients, so achalasia is often first treated as reflux; that everyone with suspected achalasia needs upper endoscopy to rule out an obstructing tumor; that balloon dilation carries a median perforation rate of 1.9% in experienced hands; and that in a randomized trial 41% had esophagitis 2 years after endoscopic myotomy against 7% after dilation, PubMed 32773454. ↩
  6. On treatment success: a systematic review of 93 articles, including 9 randomized trials of 734 patients, found pneumatic dilation 70% to 90% effective and laparoscopic myotomy 88% to 95% effective, with outcomes varying by subtype, PubMed 25965233. ↩
  7. On aspiration: retained esophageal contents can be aspirated, particularly overnight, causing cough, recurrent chest infections and aspiration pneumonia, PubMed 42030216. Staying upright for two to three hours after eating and avoiding late meals reduces this. Recurrent chest infections in someone with achalasia should prompt urgent review rather than another course of antibiotics. ↩
  8. On what triggers the nerve loss: a review found the cause still uncertain, with achalasia reported in identical twins, siblings and other first-degree relatives, and the leading explanation an autoimmune process triggered by infection in a genetically predisposed person, PubMed 22791940. ↩
  9. On Chagas disease: infection with Trypanosoma cruzi damages the nerve network of the esophagus and produces a secondary achalasia, treated with the same options as achalasia, with the choice made in light of the heart disease Chagas can also cause, PubMed 33855597. ↩
  10. On tumors that mimic achalasia: a systematic review of 140 people with pseudoachalasia, most often caused by cancer at the junction of the esophagus and stomach, found a mean age of 60, mean weight loss of 30.6 lb (13.9 kg) and 23.6% first treated as achalasia, PubMed 31989338. ↩
  11. On conditions that mimic achalasia: a 2025 review notes that Chagas disease, tumors near or distant from the esophagus, tight strictures and previous anti-reflux or weight-loss surgery can produce an achalasia-like picture, and that chronic opioid use can cause a syndrome identical to spastic achalasia, PubMed 40639355. ↩
  12. On nutrition in dysphagia: texture modification, small frequent meals, thorough chewing, sipping water between bites and remaining upright are the mainstays. Liquid and sublingual formulations matter because swallowing capsules is often the limiting factor. Weight loss before a procedure predicts poorer recovery, which is the reason for the emphasis on maintaining intake. ↩
  13. On treatment outcomes: peroral endoscopic myotomy (POEM), laparoscopic Heller myotomy with fundoplication, and graded pneumatic dilation all achieve good symptom relief in the large majority of patients with Type I and Type II achalasia. Randomized comparisons of POEM against Heller myotomy and against pneumatic dilation show broadly comparable symptom outcomes, with differing reflux profiles. Choice depends on subtype, anatomy, age and local expertise. ↩
  14. On botulinum toxin and calcium channel blockers: botulinum toxin injection at the lower esophageal sphincter gives temporary relief, typically around six months, and is generally reserved for people who are poor candidates for definitive treatment. Calcium channel blockers and nitrates provide limited benefit and are not a substitute for myotomy or dilation. ↩
  15. On post-myotomy reflux: gastroesophageal reflux is common after POEM, reported in roughly 20 to 40% and higher in some series: one long-term follow-up found reflux esophagitis in 42% of patients, PubMed 42580679. It is less frequent after Heller myotomy combined with fundoplication, which is why the fundoplication is added. Long-term acid suppression is often needed, and Barrett's esophagus surveillance becomes relevant in that context. This is a trade-off of the treatment, not a reason to avoid it. ↩
  16. On magnesium safety: people with impaired kidney function are at higher risk of adverse effects from magnesium supplements; magnesium and bisphosphonate bone medicines should be taken two hours apart, and magnesium can reduce the effect of some antibiotics, Linus Pauling Institute. ↩
  17. On food stuck in the esophagus: food bolus impaction in adults is often linked to an underlying esophageal problem, including motility disorders, can cause drooling, chest pain, vomiting and inability to swallow saliva, and needs prompt recognition and sometimes urgent removal, PubMed 29489297. ↩
  18. On perforation: endoscopic procedures are the leading cause of esophageal perforation, its symptoms are often nonspecific, and delay in diagnosis significantly increases mortality, PubMed 30335331. ↩
  19. National Center for Complementary and Integrative Health (NIH), nccih.nih.gov, and the Linus Pauling Institute Micronutrient Information Center, lpi.oregonstate.edu/mic. ↩